545 related articles for article (PubMed ID: 28092665)
1. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.
Caskey M; Schoofs T; Gruell H; Settler A; Karagounis T; Kreider EF; Murrell B; Pfeifer N; Nogueira L; Oliveira TY; Learn GH; Cohen YZ; Lehmann C; Gillor D; Shimeliovich I; Unson-O'Brien C; Weiland D; Robles A; Kümmerle T; Wyen C; Levin R; Witmer-Pack M; Eren K; Ignacio C; Kiss S; West AP; Mouquet H; Zingman BS; Gulick RM; Keler T; Bjorkman PJ; Seaman MS; Hahn BH; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC; Klein F
Nat Med; 2017 Feb; 23(2):185-191. PubMed ID: 28092665
[TBL] [Abstract][Full Text] [Related]
2. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
Caskey M; Klein F; Lorenzi JC; Seaman MS; West AP; Buckley N; Kremer G; Nogueira L; Braunschweig M; Scheid JF; Horwitz JA; Shimeliovich I; Ben-Avraham S; Witmer-Pack M; Platten M; Lehmann C; Burke LA; Hawthorne T; Gorelick RJ; Walker BD; Keler T; Gulick RM; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC
Nature; 2015 Jun; 522(7557):487-91. PubMed ID: 25855300
[TBL] [Abstract][Full Text] [Related]
3. Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers.
Nyanhete TE; Edwards RJ; LaBranche CC; Mansouri K; Eaton A; Dennison SM; Saunders KO; Goodman D; Janowska K; Spreng RL; Zhang L; Mudrak SV; Hope TJ; Hora B; Bradley T; Georgiev IS; Montefiori DC; Acharya P; Tomaras GD
Front Immunol; 2021; 12():670561. PubMed ID: 35003053
[TBL] [Abstract][Full Text] [Related]
4. Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.
Longo NS; Sutton MS; Shiakolas AR; Guenaga J; Jarosinski MC; Georgiev IS; McKee K; Bailer RT; Louder MK; O'Dell S; Connors M; Wyatt RT; Mascola JR; Doria-Rose NA
J Virol; 2016 Dec; 90(23):10574-10586. PubMed ID: 27654288
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.
Schoofs T; Klein F; Braunschweig M; Kreider EF; Feldmann A; Nogueira L; Oliveira T; Lorenzi JC; Parrish EH; Learn GH; West AP; Bjorkman PJ; Schlesinger SJ; Seaman MS; Czartoski J; McElrath MJ; Pfeifer N; Hahn BH; Caskey M; Nussenzweig MC
Science; 2016 May; 352(6288):997-1001. PubMed ID: 27199429
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with anti-HIV-1 antibodies maintains viral suppression.
Mendoza P; Gruell H; Nogueira L; Pai JA; Butler AL; Millard K; Lehmann C; Suárez I; Oliveira TY; Lorenzi JCC; Cohen YZ; Wyen C; Kümmerle T; Karagounis T; Lu CL; Handl L; Unson-O'Brien C; Patel R; Ruping C; Schlotz M; Witmer-Pack M; Shimeliovich I; Kremer G; Thomas E; Seaton KE; Horowitz J; West AP; Bjorkman PJ; Tomaras GD; Gulick RM; Pfeifer N; Fätkenheuer G; Seaman MS; Klein F; Caskey M; Nussenzweig MC
Nature; 2018 Sep; 561(7724):479-484. PubMed ID: 30258136
[TBL] [Abstract][Full Text] [Related]
7. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.
Lynch RM; Boritz E; Coates EE; DeZure A; Madden P; Costner P; Enama ME; Plummer S; Holman L; Hendel CS; Gordon I; Casazza J; Conan-Cibotti M; Migueles SA; Tressler R; Bailer RT; McDermott A; Narpala S; O'Dell S; Wolf G; Lifson JD; Freemire BA; Gorelick RJ; Pandey JP; Mohan S; Chomont N; Fromentin R; Chun TW; Fauci AS; Schwartz RM; Koup RA; Douek DC; Hu Z; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
Sci Transl Med; 2015 Dec; 7(319):319ra206. PubMed ID: 26702094
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.
Scheid JF; Horwitz JA; Bar-On Y; Kreider EF; Lu CL; Lorenzi JC; Feldmann A; Braunschweig M; Nogueira L; Oliveira T; Shimeliovich I; Patel R; Burke L; Cohen YZ; Hadrigan S; Settler A; Witmer-Pack M; West AP; Juelg B; Keler T; Hawthorne T; Zingman B; Gulick RM; Pfeifer N; Learn GH; Seaman MS; Bjorkman PJ; Klein F; Schlesinger SJ; Walker BD; Hahn BH; Nussenzweig MC; Caskey M
Nature; 2016 Jul; 535(7613):556-60. PubMed ID: 27338952
[TBL] [Abstract][Full Text] [Related]
9. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
10. A Highly Unusual V1 Region of Env in an Elite Controller of HIV Infection.
Silver ZA; Dickinson GM; Seaman MS; Desrosiers RC
J Virol; 2019 May; 93(10):. PubMed ID: 30842322
[TBL] [Abstract][Full Text] [Related]
11. Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.
Mandizvo T; Gumede N; Ndlovu B; Ndlovu S; Mann JK; Chopera DR; Singh L; Dong KL; Walker BD; Ndhlovu ZM; Lavine CL; Seaman MS; Gounder K; Ndung'u T
J Virol; 2022 Dec; 96(24):e0127022. PubMed ID: 36453881
[TBL] [Abstract][Full Text] [Related]
12. Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1.
Matsushita S; Yoshimura K; Ramirez KP; Pisupati J; Murakami T;
AIDS; 2015 Feb; 29(4):453-62. PubMed ID: 25630040
[TBL] [Abstract][Full Text] [Related]
13. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
Stephenson KE; Julg B; Tan CS; Zash R; Walsh SR; Rolle CP; Monczor AN; Lupo S; Gelderblom HC; Ansel JL; Kanjilal DG; Maxfield LF; Nkolola J; Borducchi EN; Abbink P; Liu J; Peter L; Chandrashekar A; Nityanandam R; Lin Z; Setaro A; Sapiente J; Chen Z; Sunner L; Cassidy T; Bennett C; Sato A; Mayer B; Perelson AS; deCamp A; Priddy FH; Wagh K; Giorgi EE; Yates NL; Arduino RC; DeJesus E; Tomaras GD; Seaman MS; Korber B; Barouch DH
Nat Med; 2021 Oct; 27(10):1718-1724. PubMed ID: 34621054
[TBL] [Abstract][Full Text] [Related]
14. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
[TBL] [Abstract][Full Text] [Related]
15. Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope.
Barnes CO; Gristick HB; Freund NT; Escolano A; Lyubimov AY; Hartweger H; West AP; Cohen AE; Nussenzweig MC; Bjorkman PJ
Nat Commun; 2018 Mar; 9(1):1251. PubMed ID: 29593217
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound.
Cale EM; Bai H; Bose M; Messina MA; Colby DJ; Sanders-Buell E; Dearlove B; Li Y; Engeman E; Silas D; O'Sullivan AM; Mann B; Pinyakorn S; Intasan J; Benjapornpong K; Sacdalan C; Kroon E; Phanuphak N; Gramzinski R; Vasan S; Robb ML; Michael NL; Lynch RM; Bailer RT; Pagliuzza A; Chomont N; Pegu A; Doria-Rose NA; Trautmann L; Crowell TA; Mascola JR; Ananworanich J; Tovanabutra S; Rolland M;
J Clin Invest; 2020 Jun; 130(6):3299-3304. PubMed ID: 32182219
[TBL] [Abstract][Full Text] [Related]
17. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
McGuire AT; Glenn JA; Lippy A; Stamatatos L
J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.
Ledgerwood JE; Coates EE; Yamshchikov G; Saunders JG; Holman L; Enama ME; DeZure A; Lynch RM; Gordon I; Plummer S; Hendel CS; Pegu A; Conan-Cibotti M; Sitar S; Bailer RT; Narpala S; McDermott A; Louder M; O'Dell S; Mohan S; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Mascola JR; Graham BS;
Clin Exp Immunol; 2015 Dec; 182(3):289-301. PubMed ID: 26332605
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms.
Deshpande S; Patil S; Kumar R; Hermanus T; Murugavel KG; Srikrishnan AK; Solomon S; Morris L; Bhattacharya J
Retrovirology; 2016 Aug; 13(1):60. PubMed ID: 27576440
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
